Assessment and Treatment of Proctitis
For ulcerative proctitis, start with topical 5-ASA therapy as first-line treatment, and if inadequate response occurs within 2-4 weeks, add oral 5-ASA or substitute topical corticosteroids; refractory cases require escalation to oral corticosteroids, topical tacrolimus, JAK inhibitors, S1P agonists, or biologic therapy. 1
Diagnostic Assessment
Establishing the Diagnosis
The diagnosis of ulcerative proctitis must be confirmed through ileocolonoscopy with histopathology, explicitly excluding infectious causes, Crohn's disease, drug-induced proctitis, radiation-induced damage, and trauma 2. The macroscopic extent of lesions should be limited to 15 cm from the anal verge to qualify as proctitis 2.
For histologic assessment, use one of three validated scoring systems:
- Robarts histopathology index
- Nancy index
- Geboes score 2
These provide standardized quantification of histologic inflammation for both diagnosis and monitoring.
Disease Activity Monitoring
Clinical assessment should occur within 3 months of treatment initiation 3. The monitoring approach includes:
- Fecal calprotectin (used by 75.9% of practitioners) and C-reactive protein (67.1%) for biochemical activity 3
- Endoscopic assessment at 3-6 months (34.2% of practitioners) or 6-12 months (48.4%) after treatment induction 3
- Derived total Mayo scores to assess remission status 4
A critical pitfall: approximately 40% of proctitis patients remain in remission at consultation, with the lowest remission rates (35%) seen in refractory cases 4. This underscores the need for objective monitoring beyond symptom assessment alone.
Treatment Algorithm
First-Line Therapy: Topical 5-ASA
Topical 5-ASA suppositories are the cornerstone of initial treatment 1, 5. These rectally administered formulations effectively reach the affected rectal mucosa and demonstrate efficacy comparable to corticosteroids 6.
Second-Line Options (2-4 Week Non-Response)
If topical 5-ASA fails or is not tolerated within 2-4 weeks, escalate to:
- Add oral 5-ASA to topical therapy (combination may prevent proximal disease extension) 5
- Substitute topical corticosteroid suppositories 1, 5
- Combine both approaches for left-sided disease extending beyond the rectum 5
Refractory Proctitis Management
For patients failing 5-ASA and topical corticosteroids, the treatment hierarchy is:
- Oral corticosteroids (prednisolone) for induction 1
- Topical tacrolimus 1
- Advanced therapies: JAK inhibitors, S1P agonists, or biologics 1
Among advanced therapies, anti-TNF agents are the preferred first-line choice (48.4% of practitioners) after conventional treatment failure 3. However, a concerning practice gap exists: 49% of physicians are more reluctant to initiate advanced therapy in isolated proctitis compared to more extensive disease 3, despite evidence that 33.5% of proctitis patients ultimately require advanced therapy 4.
Critical Caveat on Corticosteroids
Corticosteroids are NOT recommended for long-term maintenance therapy 1. They serve only for induction of remission. If corticosteroid taper is unsuccessful or repeated courses are needed, immediately escalate to advanced therapy 1.
Treatment Goals and Endpoints
The treatment paradigm has shifted from achieving clinical response to achieving complete remission assessed biochemically, endoscopically, and histologically 1. This treat-to-target approach aims to prevent long-term disease complications.
Maintenance therapy should continue with whichever agent successfully achieved induction, with the exception of corticosteroids 1. For patients on infliximab, consider adding purine analogues (azathioprine) for maintenance 1.
Special Considerations
Disease Burden Recognition
Proctitis significantly impairs quality of life despite being considered "limited" disease 7, 8. Common symptoms include:
- Abdominal pain (33.8%)
- Bowel urgency (22.7%)
- Fatigue (22.7%)
- Passing mucus (19.0%)
- Tenesmus (15.7%)
- Rectal bleeding (15.3%) 4
Refractory Disease Prevalence
Nearly 30% of patients develop refractory proctitis 7, and among those receiving immunomodulators or advanced therapy, only 35% achieve remission 4. This substantial treatment-resistant population requires aggressive management rather than the historical approach of minimizing therapy based on "limited extent."
Combination Therapy Considerations
Approximately two-thirds of practitioners are less likely to combine biologics with immunosuppressants in isolated proctitis compared to extensive disease 3. However, this practice may not be evidence-based and could contribute to suboptimal outcomes in refractory cases.
Surgical Consideration
Proctocolectomy is reserved exclusively for patients with ongoing symptoms despite maximal medical therapy 5. Surgery is never indicated for proctitis based on extent alone 9.